控制性促排卵中特殊人群添加重组人黄体生成素的临床应用

Application of recombinant human luteinizing hormone supplementation in the subgroup population in controlled ovarian hyperstimulation

成功的辅助生殖结局与适宜的卵巢刺激紧密相关。FSH和LH在卵泡发生和激素合成过程中扮演协同作用。LH是E2生成、卵泡最适发育、排卵和黄素化的必须因素。多数学者认为1.2U/L≤LH≤5.0U/L是卵泡发育和卵母细胞成熟的治疗窗。控制性促排卵(COH)中低LH是否需要添加重组人黄体生成素(r-hLH)一直广受争议。本文就COH中可能通过添加r-hLH获益的特殊人群及添加的剂量和时机进行综述。

Successful assisted reproductive outcome is closely related to appropriate ovarian stimulation.FSH and LH play a synergistic role in folliculogenesis and steroidogenesis.LH is critical for E2 synthesis,optimal follicle development,ovulation and luteinization.It is well accepted that 1.2 U/L≤LH≤5.0 U/L is the therapeutic window for follicular development and oocyte maturation.Recombinant human luteinizing hormone(r-hLH)supplementation in low LH patients in controlled ovarian hyperstimulation(COH)remains controversial.Here we aim to review the subgroup population to whom and when exogenous luteinizing hormone supplementation in controlled ovarian stimulation is needed.